Journal: American Journal of Cancer Research

Article Title: SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression

doi:

Figure Lengend Snippet: Effect of SERMs (Fulvestrant and MPP) and non-SERM (EGCG) to inhibit EE induced growth of MS751 ERα+ve CC xenografts during 16 days treatment period. Values represent, Mean ± SEM (n = 5). The data was analyzed by two-way ANOVA and Bonferroni test. aP < 0.05, bP < 0.01, cP < 0.001 control versus treatment and time. Control versus fulvestrant, showed significance on day 13 (a), day 16 (c). Control versus Cisplatin, showed significance on day 7 (a), day 10 (a), day 13 and 16 (c). Control versus MPP, showed significance on day 7 (a), day 10 (b), day 13 and 16 (c). Control versus MPP + Cisplatin, showed significance on day 7 (a), day 10, 13 and 16 (c). Control versus EGCG, showed significance on day 13 (a), day 16 (c). Control versus EGCG + Cisplatin, showed significance on day 10 (a), day 13 and 16 (c). Control, fulvestrant, and cisplatin groups are the same in left (A) and right (B) panel.

Article Snippet: Chemicals MPP, EGCG and EE were purchased from Cayman chemical company, USA.

Techniques: Control

Journal: American Journal of Cancer Research

Article Title: SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression

doi:

Figure Lengend Snippet: Percentage change in body weight in comparison with day 0, observed during 16 days of longitudinal treatment period. Data represents Mean ± SEM (n = 5) and * indicates a significant difference from control, as assessed by two-way ANOVA plus Bonferroni post hoc test Control versus treatment/time (*P < 0.05; **P < 0.01; ***P < 0.001). Doses were the following: Fulvestrant; 1 mg/kg/day/s.c, Cisplatin; 2 mg/kg/i.p once every 3 days, MPP; 5.4 mg/kg/i.p/day, EGCG; 21.1 mg/kg/i.p/day

Article Snippet: Chemicals MPP, EGCG and EE were purchased from Cayman chemical company, USA.

Techniques: Comparison, Control

Journal: American Journal of Cancer Research

Article Title: SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression

doi:

Figure Lengend Snippet: Representative photomicrographs of MS751 ERα+ve xenografts show sheets of large round to polygonal cells with moderate cytoplasm, vesicular nuclei and prominent nucleoli and increased mitosis (poorly differentiated epidermoid carcinomas) in the control (A), residual tumours in the Fulvestrant (B) and MPP treatment (D) groups. Cisplatin group (C) showed extensive areas of necrosis and foamy histiocytes. MPP + Cisplatin group (E) exhibited areas of 80 to 90% viable tumour and 10 to 20% necrosis. EGCG (F) and EGCG + Cisplatin (G) groups showed extensive areas of necrosis and collection of foamy histiocytes and inflammation debri. Black arrows indicate foamy histiocytes and triangle indicate necrosis (Magnification 40×).

Article Snippet: Chemicals MPP, EGCG and EE were purchased from Cayman chemical company, USA.

Techniques: Control

Journal: American Journal of Cancer Research

Article Title: SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression

doi:

Figure Lengend Snippet: Representative photomicrographs from immunohistochemical staining of ERα expression in MS751 ERα+ve tumor xenografts shows predominant cytoplasmic and membrane ERα expression with limited nuclear ERα staining in confined areas of control tumours (A). Treatment with MPP, MPP + Cisplatin and fulvestrant showed loss of ERα in all the extra-nuclear compartments (B-D). Extensive necrosis of EGCG, EGCG + Cisplatin, Cisplatin showed widespread background staining with few viable areas of tumor cells (E-G). ERα was readily detectable in the nucleus of MCF-7 (H), cell membrane and cytoplasm of EE treated MS751 cells (I) and undetectable in EE treated HeLa cells (J) (Magnification 40×).

Article Snippet: Chemicals MPP, EGCG and EE were purchased from Cayman chemical company, USA.

Techniques: Immunohistochemical staining, Staining, Expressing, Membrane, Control

Journal: Drug Metabolism and Disposition

Article Title: Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters

doi: 10.1016/j.dmd.2025.100155

Figure Lengend Snippet: Control uptake experiments with known substrates. Uptake and transcellular transport of known substrates (A) PAH for HEK-OAT1, (B) E3S for HEK-OAT3, (C, D) BSP for HEK-OATP1B1 and HEK-OATP1B3, (E, F, H) MPP + for HEK-OCT2, HEK-MATE1, and MDCK cells and (G) digoxin (Dig) for P-gp in Caco-2 cells. Substrate concentrations are given in the respective subtitles in the figure. Uptake or transcellular transport was measured after 5 minutes of incubation for HEK cells, after 60 minutes for MDCK cells, and after 240 minutes for Caco-2 cells in the presence and absence of the P-gp inhibitor valspodar (2 μ M). Data are shown as mean ± SEM resulting from 4 biological replicates, ∗∗ P < .01 vs VC/no valspodar; ∗∗∗ P < .001 vs VC ∗∗∗∗ P < .0001 vs VC/no valspodar (two-tailed unpaired Student’s t test). Val, added valspodar; intra, intracellular accumulation; apical, transcellular transport from the basal to the apical compartment.

Article Snippet: [ 3 H]-MPP + iodide (80 Ci/mmol), [ 3 H]-PAH (40 Ci/mmol), [ 3 H]-E3S (50 Ci/mmol), and [ 3 H]-digoxin (20 Ci/mmol) were from American Radiolabeled Chemicals, Inc. Poly-D-lysine hydrobromide and sodium butyrate were purchased from Sigma-Aldrich.

Techniques: Control, Incubation, Two Tailed Test